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Background and Aims: In earlier work, we identified that people affected by multiple scle-
rosis (MS) can have difficulty finding online treatment information that is up to date, trustworthy,
understandable, and applicable to personal circumstances, but does not provoke confusion or
negative emotional consequences. The objective was to develop online consumer summaries of
MS treatment evidence (derived from Cochrane Reviews) that respond to identified treatment
information needs of people affected by MS.
Methods: A 2‐phase mixed‐methods project, conducted in partnership with consumers and
an MS organisation. Phase 1 included review panels with consumers (Australians affected by
MS) and health professionals to test paper‐based treatment summaries before development,
and pilot testing of the website. Phase 2 involved an online survey after website launch.
Results: Eighty‐three participants (85% affected by MS) took part. Phase 1 participants
strongly endorsed key review summary components, including layering information, and addi-
tional sections to aid personal applicability. Participants additionally suggested questions for
health professionals. Participants across both phases were receptive to the idea of being provided
with Cochrane Review summaries online but were seeking other types of evidence and informa-
tion, such as personal experiences and the latest experimental treatments, which could not be
provided. While the small survey sample size (n = 58) limits application of the results to a broader
population, the website was viewed favourably, as a useful, understandable, and trustworthy
information source.
Conclusion: We describe a partnership approach to developing online evidence‐based treat-
ment information, underpinned by an in‐depth understanding of consumers' information needs.
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Multiple sclerosis (MS) is a chronic neuro‐inflammatory condition with
much uncertainty around individual prognosis. Treatments include a
diverse array of drugs with some confronting risk‐benefit profiles1
and many novel and experimental treatments.2 Like many health care
consumers, people affected by MS, that is, people with MS and their
families and carers, increasingly seek information about such treat-
ments online.3,4 While most trust the advice of their health profes-
sionals,3 many people affected by MS gain confidence over time to
find and interpret online treatment information.5
Within this context, it is important to provide people affected byMS
with up‐to‐date, reliable, and independent evidence‐based treatment
information. Systematic reviews, as summaries of multiple studies on a
topic, should be the basis for much of the information about benefits
and harms.6 However, previous research has found that consumers, that
is, patients, families, carers, and their advocates, can find systematic
reviews, and plain language summaries, either difficult to understand or
insufficiently detailed to use in decision making.7,8 They also want to
know how research evidence relates to them individually, and determin-
ing this can be difficult.7,9 While the evidence is building on how to best
share systematic review evidence with consumers,7,9,10 including people
affected by MS,11,12 until recently, there has been scant literature or
examples about how this translates into an online environment within
the context of MS13 and how to integrate systematic review data with
other information needs.9 Recent developments in consumer‐friendly
online presentations of benefits and harms include interactive
Summary of Findings tables and plain language summaries14 and the
MAGICApp rapid recommendations and decision aids.15
This paper describes the development of Making Sense of MS
Research,16 an Australian website launched in 2012, that provides sum-
maries of MS treatment evidence from Cochrane Reviews for people
affected by MS. We created the website as part of “Integrating and
Deriving Evidence, Experiences and Preferences” (IN‐DEEP), a mixed‐
methods study conducted in parallel in Australia5,17 and Italy.18,19
Here, we describe the Australian arm of the project.
For the first stage of IN‐DEEP, we undertook a qualitative explo-
ration of the online treatment information‐seeking experiences, pref-
erences, and needs of 60 Australians with MS and their family
members.5 We identified that people affected by MS can have
difficulty finding online treatment information that is up to date, trust-
worthy, understandable, and applicable to personal circumstances, but
does not provoke confusion or negative emotional consequences.
In stage 2, described here, we sought to respond to the unmet
treatment information needs identified in stage 1, by developing Mak-
ing Sense of MS Research.16 As such, the aim of this project stage was to
develop online consumer summaries of MS treatment that were easy
to understand and applicable to personal circumstances, met additional
information needs, relied on up‐to‐date and trustworthy sources, and
mitigated confusion and negative emotional consequences.2 | METHODS
Themethods for this projectwere informedby the principles of knowledge
translation6 and consumer participation in research.20 In knowledge trans-
lation, the focus is not just on the content andmessage being shared but is
also founded on an understanding of the target audience and the broader
context.21 Involving consumers in research has an intrinsic value of encour-
aging democracy, accountability, and transparency and anextrinsic value of
improving the quality, impact, and relevance of the research produced.22,23
In practice, both involve interactive processes that share research between
its creators and users, with varied activities and multiple iterations.6
We describe this study in 2 phases. Phase 1—developing the
website—involved the development of paper‐based treatment summa-
ries that were tested in review panels involving people affected by MS
and others, followed by website creation and pilot testing. The purpose
of these review panels and website pilot testing was to help inform the
website content and design the information presentation format.
Phase 2—website feedback survey—occurred after the website was
launched and involved an online survey of website visitors. The pur-
pose of the evaluation of the consumer summaries and the website
was to gather user feedback about the presentation and usefulness
of the consumer summaries and about website navigation. Reflecting
commonly used terminology in Australia, in this paper, we use the term
“consumer,” which means patients, families, carers, their advocates,
and representatives, interchangeably with “people affected by MS.”2.1 | Project team, and consumer and operational
advisory groups
The project team included Australian (SH, AS, MH, and RO) and Italian
researchers (GF, CC, and PM), and staff from Australian and local
(Victorian) MS societies (MPS and SS). We also sought input from 2
advisory groups convened for the project: a consumer advisory group
and an operational advisory group. The consumer advisory group
(CLC, RS, and CAM) included 2 people with MS and anMS health infor-
mation specialist. They prioritised the Cochrane Reviews to be included
on the website and provided advice on data collection and analysis, and
input intowebsite layout, content, andwording.24 The operational advi-
sory group included clinical managers (n = 2), IT staff (n = 2), and com-
munications personnel (n = 2) from the local Australian state‐based
MS organisation. They played a major role in the design and technical
aspects of thewebsite and reviewed content from a clinical perspective.2.2 | Phase 1: developing the website
The development of the treatment summaries from the Cochrane
Reviews, along with all additional website content, and overarching
structure and format, was informed by existing literature and best
practice documents. There were also shaped by the findings of the
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with MS, and others, described in here (IN‐DEEP stage 2).2.2.1 | Developing paper‐based summaries
We selected 2 Cochrane Reviews of MS treatments (prioritised by the
consumer advisory group) and developed them into paper‐based
treatment summaries for feedback by the review panels. We chose
these reviews (one on a medication used by many people affected by
MS25 and the other about exercise26) because of the relevance of this
information to many people and because of the different types of data
to be summarised. We followed research‐based principles for present-
ing treatment information to consumers, such as layering,27 and used a
combination of words, numbers and pictures, and absolute, rather than
relative, frequencies.28,29 The information we presented differed from
the usual format of a Cochrane Review in the following ways: It was
significantly shorter and focused on key information only (ie, inclusion
criteria and results); plain language was used throughout; graphical
illustrations of numerical information were used; and novel sections,
explaining how results applied to individuals and questions that
consumers can ask their health professionals, were included.2.2.2 | Review panels
The aim of the review panels was to seek formal feedback on the paper‐
based treatment summaries before they were transferred to an online
format. Recruitment involved purposive sampling from participants of
the first stage of the IN‐DEEP project5 and from the networks of the
project team and the MS organisation. We sought to include people
affected by MS, clinicians, and staff of the MS organisation.
One week prior to the review panels, we mailed participants a
pack containing a document explaining the nature of the project, the
2 treatment summary templates, and information and consent forms.
We included a one‐page feedback form, whereby participants were
encouraged to record their immediate impressions of the templates
and bring this to the panel discussion.
We held 2 review panels (a form of group interview)30,31 at a local
MS organisation office, with each panel session lasting 2 hours. Two
researchers were involved as facilitator (SH) and note‐taker (AS). The
following 5 questions, based on those used in the DECIDE project
(work package one),32 were used to guide the discussion: “do you
understand the information presented?”; “is it helpful to you?”; “is
there anything missing?”; “is there anything superfluous?”; and “do
you have any suggestions for improvement?”
One researcher (AS) collated participants' feedback sheets, the
researchers' detailed written notes, and audio recordings of the review
panel sessions, which were reviewed by a second researcher (SH). We
used the audio recordings to supplement the written notes. One
researcher (AS) grouped all participant feedback under 1 of 5 catego-
ries: one overarching category on content, formatting, or general
feedback, and 4 specific categories corresponding to the 4 main
sections of the treatment summary template (ie, “The short answer,”
“The detailed answer,” “What does this mean for me?” and “Using this
information”). Within each of these categories, individual feedback
items were grouped according to “likes,” “dislikes,” and “suggestions.”
We considered the implications of each individual feedback item,culminating in a list of recommendations for changes and/or additions
to the individual review templates or, more broadly, for the website.
We subsequently discussed and agreed on the recommendations with
the project team and consumer advisory group.
2.2.3 | Developing the pilot website
We created a pilot website after integrating feedback from the review
panels. To guide the website layout and format, we used the HONcode
principles33 and the Harvard School of Public Health Guidelines.34
Web design and functionality were informed by the Web Accessibility
Initiative Guidelines,35 as well as by input from the consumer advisory
group. To cater for people who did not have access to the Internet and
to enable website visitors to discuss the treatment summaries with
their health professional, we created downloadable PDF versions of
the treatment summaries. MS organisation clinical managers and an
MS organisation librarian reviewed the content for relevance to the
Australian context and for readability.
2.2.4 | Website pilot testing
After the development of the pilot website, we invited people affected
by MS to take part in pilot testing. Participants were recruited from
people who took part in the review panels and through the networks
of the project team.
We asked pilot testing participants to visit the website and complete
an online survey (see Supporting Information). Participants subsequently
took part in a 30‐minute telephone interview to discuss their survey
responses with a researcher who had not been involved in the develop-
ment of the website (MH). In response to the survey data and interview
responses, we made minor changes to the website, such as incorporating
additional links to further information and reordering of the site page tabs.
2.3 | Phase 2: website feedback survey
Following incorporation of the changes after pilot testing, we launched
the website in November 2012, with promotion to relevant organisa-
tions and individuals across Australia and internationally. The primary
promotion strategy was through the networks of the local MS organi-
sation and MS Australia, via their websites and social media pages, e‐
mailing lists, and newsletters.
2.3.1 | Online survey
The purpose of the evaluation of the consumer summaries and the
website was to gather user feedback about the presentation and
usefulness of the consumer summaries and about website navigation.
Development of the survey was based on the unmet treatment infor-
mation needs identified in stage 1 of IN‐DEEP.5 On the basis of these
unmet needs, we developed survey sections with brief descriptive
rationales for survey questions. Two project team members (RO and
MH) developed the survey questions using a rapid literature review
and their extensive survey‐writing experiences and resources. The
questions chosen for survey sections were informed by previously
validated patient‐reported outcomes measures.36,37 Collaboration
with the research team about survey content was ongoing. The final
survey included qualitative and quantitative questions under sections
about users' initial expectations of the site and what else they would
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and if users might use the information to consult health professionals;
the site's usability; and demographic questions. The survey was pilot
tested with people affected by MS as part of the broader website
pilot testing, and some minor revisions were made to improve user
understanding of the questions. This survey was designed for the
purpose of gathering user feedback about presentation of the online
consumer summaries and website usability and was not intended
for use in other contexts. We included the survey on the website
for 2 months after the site was launched (see Supporting Information)
but did not actively recruit people to complete the survey. It
displayed as a box of highlighted text that website users could accept
or decline.2.4 | Ethical approval and informed consent
Participants in all phases provided informed consent to participate, via
a written or online form. We received approval from the Human Ethics
Committee, Faculty of Health Sciences, La Trobe University (numbers
11‐169 and 12‐128). We offered review panel participants a $50
voucher for their participation. We did not offer reimbursement to
participants in other project phases.TABLE 1 Participant demographic characteristics
Characteristics
Developing the Website
Review Panels (N = 16) Pi
Participants (n, %)
People with MS 10 (63)
Family members 1 (6)
Health professionals/otherb 5 (31)
Gender (n, % female) 10 (63)
Age (n, %)
21 to 40 y 3 (19)
41 to 65 y 11 (69)
66 y and over 2 (13)
Highest education levelc (n, %)
High school (not completed) 0 (0)
High school (completed) 1 (9)
Occupational certificate 6 (55)
University degree 4 (36)
Time with MSe (y; median, range) 19 (2 to 24)





Abbreviations: MS = multiple sclerosis; N, total number of participants; NA, not
remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis.
aTwenty‐two participants did not provide full demographic details, so none of th
to 58.
bIncluded neurologists, MS nurses, and MS organisation staff.
cPeople with MS and family members only.
dPeople with MS only.
eNot asked of people with MS in the review panels.3 | RESULTS
3.1 | Participants
A total of 83 participants took part of the project, participating in
review panels (n = 16), website pilot testing (n = 9), or by completing
the website feedback survey (n = 58) (see Table 1). Of the 61 partici-
pants who provided demographic information, the majority were
people with MS (75%) or family members of people with MS (12%).
Over two‐thirds of participants were female (71%) and aged between
41 and 65 years (73%). All but one participant resided in Australia.
Approximately half of the participants affected by MS had a university
degree (48%), although those in the final project stage (website feed-
back survey) included a broader range of educational backgrounds,
with 34% of respondents having an educational level of high school
or below. The median length of time since MS diagnosis was 8 years
(range < 1 to 30 years), and most participants (69%) had the relaps-
ing‐remitting form of the disease.3.2 | Phase 1: developing the website
We present the results of this phase grouped under the 6 aims of the
website.Website Feedback Survey
Total
(N = 83)lot Test (N = 9) Online Survey (N = 58)a
6 (67) 30 (83) 46 (75)
3 (33) 3 (8) 7 (12)
0 (0) 3 (8) 8 (13)
7 (78) 22 (73) 39 (71)
3 (33) 6 (20) 12 (22)
6 (67) 23 (77) 40 (73)
0 (0) 1 (3) 3 (6)
0 (0) 5 (17) 5 (10)
1 (11) 5 (17) 7 (14)
4 (44) 4 (13) 14 (28)
4 (44) 16 (53) 24 (48)
4.5 (1 to 21) 4 (<1 to 30) 8 (<1 to 30)
5 (83) 20 (67) 25 (69)
1 (17) 5 (17) 6 (17)
0 (0) 3 (10) 3 (8)
0 (0) 2 (7) 2 (6)
available; PPMS = primary progressive multiple sclerosis; RRMA; relapsing
e total number of participants for each demographic characteristics adds up
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To present the treatment information in a format that was straightfor-
ward and clear, we created 2 sections (the “short answer” and the
“detailed answer”) to summarise the benefits and harms of the treat-
ment, so that the information was effectively layered.27 In “the short
answer” section, we provided a one‐paragraph summary of the
Cochrane Review results. In “the detailed answer” section, a combina-
tion of words, numbers, and graphical images was used to describe the
effect of the intervention compared with placebo, on the main out-
comes collected in each review, thereby presenting the same review
findings in 3 different formats28,29 (see Figure 1). We expressed abso-
lute numbers as natural frequencies (ie, 5 of 100).
Review panel participants endorsed the concept of layering the
information and providing detailed scientific information in a combina-
tion of formats. Some of the nonconsumer participants were con-
cerned about consumers' abilities to make sense of the information,
but this was not reflected by consumer participants. There were mixed
responses to the 100 smiley faces graphic that we used in the review
panel sessions (see Kasper's multifigure pictographs12 for an example).
After consultation with colleagues, a new horizontal comparison
graphic was used on the website instead (see Figure 1). Several partic-
ipants suggested that the addition of a hyperlinked glossary would be
preferable to trying to explain scientific terms in the text. The glossary
was subsequently created for the website.3.2.2 | Applicable to personal circumstances
To provide treatment information that was more personally applicable,
we created an additional section, specific to each treatment summary,
called “Does this apply to me?” There, we described the characteristics
of the people included in the studies and the parameters of the inter-
ventions studied therein.9 We also added a section called “Questions
for my health professional” that was specific to each review.33 We
developed a set of questions, in consultation with the consumer
advisory group, that consumers could use as a prompt for discussionFIGURE 1 Screenshot showing presentation of the evidence in “the detaiwith their health professionals. Example questions included “How soon
after diagnosis is it recommended to take interferons?” and “What kind
of rehabilitation would be right for me?” Both the “Does this apply to
me?” and “Questions for my health professional” sections were
strongly endorsed in the review panels as ways to help readers apply
the information to their specific situation.3.2.3 | Meets additional information needs
To acknowledge the additional information needs of consumers, we
created a section called “Find out more,” with the aim of connecting
readers to their local MS organisation and providing links to other
online information and evidence sources (selected in consultation with
MS organisation staff).9,33 This was one of the most strongly endorsed
concepts in the review panels and the pilot testing, but many con-
sumers wanted more information and links than those provided. Some
review panel participants wanted links to patient websites where they
could read about “real people's” responses to treatments. Others
wanted more detailed information about interventions, such as what
specific types of exercise (eg, walking or gym classes) one might look
at starting or practical tips on how the medications were administered.
While the scope of the project was limited to treatment informa-
tion only, we provided links to MS organisation resources and created
a new section called “New to MS?” with some brief information about
MS and a range of web links for further information. In pilot testing, we
found that participants were expecting more treatment topics on the
website. To address this, we created a poll on the website with 5
additional review topics and invited website visitors to vote for the
topic to be summarised next. Visitors could leave their email address
if they wished to be notified when new treatment summaries were
added to the website.3.2.4 | Trustworthy
At the review panels, there were questions about Cochrane and how
Cochrane Reviews were created. For example, some participants askedled answer”
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response to this, we created a Frequently Asked Questions page, drawn
from some of the questions posed at the review panels (for example,
“What is the Cochrane Collaboration?” and “Why don't the treatment
summaries always give a clear answer?”), and a page called “About
the Research,” which explained the website development process. In
addition, logos from the project partners of La Trobe University, the
MS organisation, and Cochrane were included in the footer of every
page to make clear the independence of the website creators from
industry influence.33
3.2.5 | Up to date
To ensure website visitors would know the information was up to date,
we included the date of the review publication and the search dates for
each Cochrane Review that was summarised.33 Review panel partici-
pants endorsed the inclusion of these dates but queried the accuracy
of the treatment information because the reviews were published
more than 2 years earlier. As such, in addition to the information about
the date of publication, we included a statement about whether or not
newer studies had been published since that time. We only included
Cochrane Reviews on the site when we were confident that no further
trials had been published that met the inclusion criteria for the review
(as advised by the Cochrane Multiple Sclerosis and Rare Diseases of
the Central Nervous System Review Group).
To align available Cochrane Review topics with consumer prefer-
ences, we asked the consumer advisory group to prioritise the reviews
to be included on the website. The prioritisation criteria included the
expected interest to people affected by MS and how current the
review was. Unfortunately, the Cochrane Reviews on topics of broad
interest such as exercise,26 diet,38 and vitamin D supplementation39
were not, at that time, sufficiently up to date to be included. The
final reviews selected for the website were on immunotherapies for
different types of MS,25,40-42 hyperbaric oxygen therapy,43 and
rehabilitation.44
3.2.6 | Mitigates confusion and negative emotional
consequences
To mitigate confusion or unnecessarily negative emotional conse-
quences, consumer advisory group members reviewed the language
used in the summaries, to ensure that it was appropriate to a broad
range of consumers. We also added a question to the Frequently Asked
Questions section to offer reasons as to why the review summaries
could not always provide clear answers. To mitigate the risk of confu-
sion or concern for website readers, we included questions such as
“Why do these numbers look different from what I have seen else-
where?” The website encouraged readers to contact their local MS
organisation if they were concerned about conflicting information.3.3 | Phase 2: website feedback survey
Once launched, the website received 3873 visits (75% of which were
unique visits) in the 2‐month period during which the feedback survey
was live. During this evaluation period, 61 people elected to respond
to the survey, with 58 useable responses included in the analysis
(responses from 3 people were too incomplete to include). Given wedid not actively recruit participants to the survey, but instead
recruited them to view the website, the small sample size is not
unexpected but does limit interpretation of the usefulness of the site
to a broader population. However, of those who completed the
survey, nearly 80% (n = 46) responded positively to the research
summaries and the website as a whole. As well as quantitative data,
respondents gave free‐text responses that indicated they found the
information and website layout to be clear, aesthetically pleasing,
and easy to navigate and understand. Overall, the presentation of
the benefits and harms of each intervention was well received, with
more than 75% of respondents agreeing or strongly agreeing with
questions about understanding benefits and risks (see Supporting
Information, S2 Table).
Other questions were designed to probe reflections about
personal applicability (“The website has helped me to understand
how the treatments might be useful for me”), trustworthiness
(“The Cochrane Collaboration is a trustworthy source of information
about treatments for health conditions”), meeting additional informa-
tion needs (“I feel the About the Research section helped me to under-
stand the summaries about MS treatments”), and emotional
consequences (“I find it frightening to read about the risks of these
treatments”). These were rated as “agree” or “strongly agree” by
approximately two‐thirds (61%‐71%) of participants.
The main reasons for dissatisfaction with the information in the
summaries were that they did not cover the latest approved and exper-
imental MS medications and treatments, or nonmedical treatments.
Questions with the lowest endorsement were about whether or not
participants now felt able to make an educated decision about the
treatments (21%), if the website had helped them understand how
the treatments might be useful for them (19%), if the website met their
information needs (17%), and if they found the “Does this apply to
me?” section useful (17%).4 | DISCUSSION
In this study, we sought to address the unmet treatment information
needs of people affected by MS, as established by phase 1 of this pro-
ject, by developing a website based on MS Cochrane Review summa-
ries. We undertook all project stages in partnership with people
affected by MS and with the local MS society.24 As a consequence
of this stakeholder consultation, the website was underpinned by an
in‐depth understanding of treatment information–seeking experiences
of people affected by MS. Responses across all project phases indi-
cated there was a general receptivity by people affected by MS to
the concept of having online, independent, evidence‐based treatment
information. The website feedback survey responses, while modest
in number, suggest the information was understandable, viewed as
trustworthy, and addressed how people might apply the information
to themselves. While the treatment summaries included information
that was up to date, in that is was recent evidence, the feedback across
all project stages and phases was that respondents wanted us to
incorporate evidence about the latest, and sometimes experimental,
treatments, which were not available as Cochrane Reviews at the time
of this research.
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reviews of treatment research,45 and systematic reviews should form
the basis of evidence‐based treatment information shared with con-
sumers,6 they are insufficient for a complete treatment information
website. Consumers also need general information about the disease
and practical information, such as how treatments are administered.46
Additional challenges of using Cochrane Reviews are that they can
only provide an answer if there is sufficient existing trial evidence
and, like all systematic reviews, can date quickly in fast‐moving
fields.47 This makes it particularly challenging to provide up‐to‐date
information that includes coverage of new or experimental treatments
on such a website. Originally, our treatment summaries were intended
to be incorporated on our MS partner's website (where much of this
additional information is provided). However, due to unforeseen
circumstances during the project, we created a stand‐alone website
to house the summaries. So, while we provided links to local MS orga-
nisations for further information, it was beyond the project scope and
resources to provide all this additional information.
Similarly, the inclusion of personal narratives, or stories of the
illness experiences of others in evidence‐based websites, is an emerg-
ing issue for health information providers. Echoing our results, other
researchers have found that consumers want to know about the
personal experiences of people with health conditions,48,49 but there
is uncertainty among the research community about how these expe-
riences can be incorporated into evidence‐based resources. Personal
narratives do affect people's judgment and choices, but how to harness
this to facilitate, as opposed to hinder, patients' decision making is
unclear.50 The use of scientifically rigorous methods to source and
summarise personal narratives, such as those underpinning the Italian
IN‐DEEP website51 and the HealthTalk website,52 offers, at least, a
partial solution to this problem.
Our findings affirm the importance of partnerships between
evidence producers and trusted information providers, such as peak
bodies and member organisations. Not only do such organisations
provide some of the additional information that consumers seek, but
also groups like MS societies are considered trustworthy sources of
health information.3 This is important within the context of Cochrane
reviews, given they were unfamiliar to consumers in our study. This
unfamiliarity has been found by others to result in scepticism about
the trustworthiness of information based on Cochrane Reviews.9,49
Additionally, presenting the evidence from systematic reviews is a
science in itself. It requires a solid understanding of evidence‐based
health care, the evolving body of health communication research, and
information design principles that may be beyond those without spe-
cialist training.53 Better links between researchers and information
providers could facilitate the integration of evidence from systematic
reviews with other information that consumers need, and aid its
dissemination.54
Subsequent to the IN‐DEEP study, researchers have experimented
with new and interactive ways to present treatment benefits and risks,
online.32 Recent examples include interactive Summary of Findings
tables and plain language summaries,14 and the BMJ's consumer‐
friendly rapid recommendations.55 While their graphical presentation
would likely improve the presentation of benefits and harms used on
our website, our results speak to the need for embedding suchresources within the broader information and support needs of
consumers. Notably, a recent randomised controlled trial of web‐based
pictorial formats to present MS treatment information revealed that
the animated graphical presentations of benefits were less well under-
stood, compared with static presentations.12
Another relevant development is a broadening of systematic
review approaches, including network meta‐analysis (where multiple
interventions can be compared head‐to‐head),56 mixed‐method
reviews (where quantitative data are synthesized with qualitative
experience data),57 and reviews of observational data about side
effects.58 These types of reviews open the door for evidence summa-
ries to better meet consumer needs, by presenting empirically derived
comparative effectiveness, longer‐term data on potential harms, and
the lived experience of others.
We acknowledge a number of limitations. First is the small number
of participants who completed the online survey, limiting application of
the evaluation results to a broader population. The low response rate
to the survey may be due, in part, to dissemination or recruitment
shortcomings: We were reliant on our project partners for website
promotion, and we elected to promote the website, rather than explic-
itly recruit people to complete the survey. Alternatively, those who did
not find the website helpful may not have chosen to complete the
survey, potentially biasing results towards more favourable responses.
Second, it is unclear how well the website caters to those with low
literacy levels. The educational background of consumers and family
members involved in the development was high (mainly university edu-
cated), and we did not use a standardised tool (eg, Flesch‐Kincaid
Grade) to assess the readability of the website.59 However, the fact
that we received largely positive feedback from survey responses,
including from those who did have limited levels of education, suggests
we may have met, at least, some of the information needs of people
with limited literacy. A final limitation was that the assessment of
important concepts, such as understanding, were self‐reported, rather
than objectively measured. A more objective measure of understand-
ing is likely to have generated more modest results,12 although this
was not within the scope of this project.5 | CONCLUSION
This paper describes an approach to developing evidence‐based
treatment information that is underpinned by in‐depth understanding
of the information needs of consumers. This understanding was
facilitated by the research team's ongoing partnership with consumers,
throughout the development of the Cochrane Review information
summaries, and the website that hosts them. The evaluation indicates
that some of the unmet treatment information needs of people with
MS were met through this novel partnership approach. Equally, we
have demonstrated that consumers seek more than just the informa-
tion contained in Cochrane Reviews to help them understand and
apply treatment information. Future projects that include partnership
with consumers, as well as with peak health organisations and other
treatment information providers, may offer opportunities to fulfil these
additional consumer treatment information needs that extend beyond
treatment risks and benefits.
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